
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1172 | 991 | 1172 | 950 | 1723 | - |
Fund Return | 17.17% | -0.93% | 17.17% | -1.69% | 11.49% | - |
Place in category | 794 | 1024 | 794 | 1726 | 211 | - |
% in Category | 30 | 37 | 30 | 72 | 14 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
PG S Listed Infrastructure USD I Ac | 452.94M | 4.52 | 1.79 | 3.76 | ||
PG S Listed Private Equity USD P Ac | 397.92M | 22.59 | 5.12 | 12.20 | ||
Rezco Glbl Flxbl Fund A USD | 36.53M | -0.91 | 2.32 | - | ||
LU0803005494 | 44.77M | -0.35 | 1.10 | 0.62 | ||
PPF CP Global BioPharma Fund I USD | 16.29M | 3.97 | -6.29 | -1.71 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Capital Group New Perspective Fuzgu | 15.9B | 3.33 | 7.87 | 10.49 | ||
Capital Group New Perspective Fubu | 15.9B | 3.23 | 7.06 | 9.62 | ||
Capital Group New Perspective Fubdu | 15.9B | 3.18 | 7.05 | 9.61 | ||
Cap Group New Perspective lux C | 15.9B | 3.45 | 8.73 | - | ||
Cap Group New Perspective lux ZL | 15.9B | 3.38 | 8.10 | 10.67 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Xylem | US98419M1009 | 3.09 | 122.11 | +0.92% | |
ASML Holding | NL0010273215 | 3.02 | 652.60 | +1.59% | |
Intuit | US4612021034 | 3.02 | 592.58 | +1.94% | |
Eli Lilly | US5324571083 | 2.96 | 809.69 | +1.00% | |
Palo Alto Networks | US6974351057 | 2.93 | 179.14 | +1.60% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Buy |
Summary | Strong Sell | Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review